Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Feb 26, 2026
Linde plc (LIN) Stock Analysis: Strong Execution Meets Conservative Outlook

Linde plc (LIN) Stock Analysis: Strong Execution Meets Conservative Outlook

Key Takeaways

  • Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion.

  • 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.

  • Analyst consensus price target sits near $509, reflecting a generally constructive outlook despite mixed rating changes.

  • Shares dipped after earnings on cautious guidance but have since stabilized.

  • Restructuring initiatives and clean energy investments position Linde for potential margin expansion in 2026.

  • Street forecasts call for roughly 4.4% revenue growth to $35.5 billion next year.

Market Snapshot: Premium Valuation, Steady Fundamentals

Linde plc shares have navigated a volatile industrial backdrop with relative resilience. After an initial post-earnings pullback, the stock has recovered and stabilized, reflecting investor confidence in its strong cash flow profile and high-visibility project pipeline.

Operating margins remain best-in-class within the industrial gases sector, supported by disciplined pricing and ongoing productivity initiatives. While traditional manufacturing volumes face pressure, growth in electronics, clean energy, and specialty gases continues to anchor the long-term thesis.

Earnings Review: Beat on Results, Caution on Outlook

Linde’s Q4 2025 results modestly exceeded expectations:

  • Adjusted EPS: $4.20 (vs. $4.18 consensus)

  • Revenue: $8.76 billion (up 6.3% year-over-year)

  • Operating cash flow: $3.0 billion (up 8%)

Full-year revenue reached $34 billion, with underlying sales growth of 3%, driven by 2% pricing gains and 1% volume growth from project startups.

The company returned $7.4 billion to shareholders in 2025 through dividends and buybacks, underscoring its commitment to capital returns.

Why Shares Initially Declined

Despite the earnings beat, shares fell more than 2% following the release. The reaction stemmed from 2026 guidance viewed as conservative:

  • Full-year 2026 EPS guidance: $17.40–$17.90

  • Q1 2026 EPS guidance: $4.20–$4.30

The midpoint of full-year guidance came in slightly below consensus expectations of $17.83. Management assumed flat base volumes and a modest 1% foreign exchange tailwind, reflecting ongoing softness in manufacturing and chemicals.

Project Backlog: Growth Visibility Into 2026

A central pillar of Linde’s investment case is its record $10 billion project backlog — approximately two-thirds tied to clean energy initiatives.

Management expects $2.5–$3.0 billion in projects to begin operations during 2026, providing incremental revenue visibility. Key areas include:

  • Hydrogen infrastructure

  • Carbon capture and storage

  • Electronics and semiconductor-related gases

Demand linked to AI-driven semiconductor production continues to offset cyclical industrial weakness in other segments.

Analyst Reaction: Mixed but Generally Constructive

Analyst responses following earnings were varied:

Downgrades:

  • JPMorgan lowered its rating to Neutral from Overweight, citing flat organic growth and potential pricing pressures.

  • DZ Bank downgraded to Hold from Buy.

Target Increases and Positive Views:

  • Morgan Stanley raised its target to $530 (Buy).

  • UBS lifted its target to $550.

  • Citi increased its target to $545.

  • Mizuho raised its target to $525.

  • BMO Capital moved its target to $507 (Outperform).

Consensus price targets cluster around $509–$510, suggesting moderate upside from recent trading levels near $468.

Restructuring and Margin Expansion

Linde recorded $230 million in restructuring charges during Q4 as part of cost optimization efforts. Benefits are expected to materialize in the second half of 2026.

Management continues to target annual margin expansion of 30–50 basis points, driven by:

  • Productivity improvements

  • Portfolio optimization

  • Pricing discipline

  • Network density efficiencies

Helium and rare gas oversupply created a 1–2% EPS headwind during the quarter, but long-term fundamentals in specialty gases remain intact.

Capital expenditures are guided to $5.0–$5.5 billion in 2026, supporting backlog execution and growth projects.

2026 Outlook: Key Factors to Watch

1. Clean Energy and Electronics Momentum

Execution on backlog projects — particularly hydrogen and electronics-related facilities — will be critical. Semiconductor capacity expansion and AI infrastructure growth remain structural demand drivers for specialty gases.

2. Industrial Volume Recovery

European manufacturing weakness and global industrial softness remain near-term headwinds. A cyclical recovery could provide incremental upside beyond current guidance assumptions.

3. Margin Discipline

Investors will monitor whether restructuring benefits exceed the historical 30–50 basis point annual expansion range. Return on capital remains strong in the low-to-mid 20% range despite elevated CapEx.

4. Commodity and Specialty Gas Pricing

Helium oversupply and rare gas pricing pressures bear watching, particularly if industrial demand remains subdued.

Bottom Line

Linde continues to demonstrate operational discipline, strong cash generation, and long-term growth visibility through its record backlog. While conservative 2026 guidance prompted an initial selloff, underlying fundamentals — including pricing power, clean energy investments, and semiconductor-driven demand — remain intact.

Tickeron AI Perspective

Disclaimers and Limitations

Related Ticker: LIN

Contributor

Dem Sem's AvatarDem Sem|Expert

LIN's RSI Oscillator recovers from oversold territory

The RSI Indicator for LIN moved out of oversold territory on August 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In of the 25 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 53 cases where LIN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 14, 2026. You may want to consider a long position or call options on LIN as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LIN advanced for three days, in of 326 cases, the price rose further within the following month. The odds of a continued upward trend are .

LIN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for LIN turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

LIN moved below its 50-day moving average on July 17, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LIN crossed bearishly below the 50-day moving average on July 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for LIN entered a downward trend on August 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LIN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.695) is normal, around the industry mean (7.130). P/E Ratio (31.145) is within average values for comparable stocks, (39.601). Projected Growth (PEG Ratio) (2.059) is also within normal values, averaging (2.441). Dividend Yield (0.013) settles around the average of (0.018) among similar stocks. P/S Ratio (6.365) is also within normal values, averaging (99.661).

Notable companies

The most notable companies in this group are DuPont de Nemours (NYSE:DD), Chemours Company (The) (NYSE:CC).

Industry description

The specialty chemicals sector includes companies that produce chemicals and industrial gases, which are of relatively high-value, often made to customer specifications. Examples of specialty chemicals are electronic chemicals, industrial gases, coatings, adhesives and sealants, industrial and institutional cleaning chemicals. The products are often valued on the basis of their purposes/performances rather than for their composition. Linde Plc, Ecolab Inc., Air Products and Chemicals, Inc., and Dow, Inc. are some of the largest companies making specialty chemicals.

Market Cap

The average market capitalization across the Chemicals: Specialty Industry is 12.08B. The market cap for tickers in the group ranges from 47 to 222.53B. LIN holds the highest valuation in this group at 222.53B. The lowest valued company is GTBT at 47.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Specialty Industry was 1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 6%. STDN experienced the highest price growth at 58%, while OEC experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Specialty Industry was -32%. For the same stocks of the Industry, the average monthly volume growth was -47% and the average quarterly volume growth was -44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 57
Price Growth Rating: 51
SMR Rating: 78
Profit Risk Rating: 80
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
LIN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a producer of industrial gas

Industry ChemicalsSpecialty

Profile
Details
Industry
Chemicals Specialty
Address
10 Riverview Drive
Phone
+1 203 837-2000
Employees
65177
Web
https://www.linde.com
Interact to see
Advertisement
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Cincinnati Financial (CINF) reports Q4 2025 earnings on February 9, 2026, after market close, with consensus EPS of $2.86–$2.89 and revenue around $2.91 billion. Allstate (ALL) recently reported Q4 2025 EPS of $14.31, well above the $8.72 estimate, with revenue of $17.3 billion on February 4, 2026.
(AZN) AstraZeneca’s full-year 2025 results, set for February 10, 2026, cap a year of sustained growth amid competitive pressures. Following 21% total revenue growth in FY 2024 and 19% core EPS expansion, AZN has maintained momentum with 11% revenue growth through nine months of 2025. The report offers insight into:
Gilead Sciences (GILD): Q4 2025 earnings due February 10, consensus EPS $1.83, revenue $7.68B. Growth driven by HIV franchise; oncology investments like Trodelvy may offer upside. Amgen (AMGN): Reported Q4 2025 EPS $5.29 vs $4.73 expected, revenue $9.9B (+9% YoY). Strong 2026 guidance: $37–38.4B revenue, $21.60–23.00 non-GAAP EPS.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
CME Group delivered record 2025 revenue of $6.52 billion, up 6% year-over-year. Q4 adjusted EPS of $2.77 exceeded expectations.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.